



News Updates: May 6, 2014

Patents/ Compulsory Licensing/ Intellectual Property

Publication: The Times of India

Edition: National

Date: May 6, 2014

Headline: [US faces pressure to take India to WTO](#)

Synopsis: The US government is coming under intense pressure from lawmakers to act against India at the World Trade Organization (WTO) for what they say are violations of patent rules. The tough stance adopted by US lawmakers raises the pressure on the new Indian government to swiftly swing into action to check against potential damage to bilateral trade ties, which have taken a knock in recent months. The demand to move the WTO was made during a meeting of the Senate finance committee on the US administration's trade policy agenda last Thursday, a day after the US Trade Representative released a report where it refused to downgrade India for its intellectual property rights (IPR) regime.

Website: Firstpost

Edition: Online

Date: May 5, 2014

Headline: [Can BJP, Modi really take Arvind Panagariya's advice on economy?](#)

Synopsis: Prof Arvind Panagariya speaks about the BJP manifesto which includes protection of intellectual property (IP) and strengthening of the manufacturing sector. The question is whose intellectual property will it protect? India's or the MNCs? While protecting the intellectual property of MNCs how can it strengthen manufacturing? Strengthening IP is one of the worst neo-liberal misadventures that India can jump into - a demand that countries such as the US have been making with direct and indirect threats. Its impact is clearly visible in the pharma sector, wherein the strong IP-regime can roll back India's hard-earned health gains.

FDA

Publication: The Economic Times

Edition: National

Date: May 6, 2014

Headline: [US FDA asks Indian pharma leaders to make quality, their top priority](#)

Synopsis: Top management of drugmaking companies must make quality control their top priority, said a senior US Food and Drug Administration (FDA) official at Hyderabad kicking off a series of FDA-Drug Controller General of India workshops to be held this year for Indian pharma companies to help them comply better to the US prescribed standards. "Companies must ensure that they are saying what they do and they do what they say and demonstrate that they did it" said Leslie Ball, deputy director, office of international program, FDA. Since the beginning of last year, there's been a spike in "violations" at India based drug plants, according to data from FDA's Centre for Drug Evaluation and Research, the US drug safety office. The sites of leading drugmakers such as Ranbaxy Laboratories, Wockhardt, Strides ArcolabB and Sun Pharma are on the list. Many of these allegations relate to 'data-fudging'.

Similar reports in-

Business Standard- ['Peer pressure crucial to ensure quality in pharma'](#)

Business Today- [USFDA lists out expectations from Indian pharma](#)

Moneycontrol- [USFDA, CDSCO join hands to hold workshops for pharma cos](#)

General Industry

Publication: Mint

Edition: National

Date: May 6, 2014

Headline: [WHO declared Polio global emergency as conflicts fuel spread](#)

Synopsis: The World Health Organization (WHO) on Monday declared the international spread of wild polio virus in 2014 a public health crisis and asked 10 affected countries to treat the issue as a national emergency apart from imposing some conditions on travellers. The move comes barely a month after WHO certified South-East Asia, which includes India, as a polio-free region.

Similar reports in-

The Hindu- [WHO sounds alert on polio](#)

The Times of India- [WHO issues travel restrictions on Pakistan over polio spread](#)

The Wall Street Journal- [Spread of Polio Is World Health Emergency, WHO Says](#)

NDTV- [Polio's Return Prompts Global Health Warning](#)

Publication: The Hindu Business Line

Edition: National

Date: May 6, 2014

Opinion piece: Tony O. Elumelu, chairman of the Heirs Holdings group, Lagos

Headline: [CSR as an anti-poverty instrument](#)

Synopsis: The Indian government has introduced the first step of a potential gamechanger, and we in Africa have taken note. A new law enacted this month makes it mandatory for private corporations to invest at least 2 per cent of their profits in corporate social responsibility (CSR). The private sector in India now has a unique opportunity to respond to the collective aspirations of an entire country and accelerate action towards achieving the MDGs on hunger, health and sustainability. We applaud India for this.

Publication: Mint

Edition: National

Date: May 6, 2014

Headline: [Sanofi says Shan5 vaccine approved for purchase by UN agencies](#)

Synopsis: A five-in-one vaccine for children made by Sanofi Pasteur Holding Ltd, the vaccines division of France's Sanofi SA, is back on the approved list of the World Health Organization (WHO) after four years of disqualification. The so-called prequalification status by the global health body qualifies the Shan5 vaccine for purchase by United Nations agencies and makes it eligible to receive funding from Global Alliance for Vaccines and Immunization (GAVI), a public-private partnership that focuses on saving children's lives by increasing access to immunization in developing nations.

Similar reports in-

Business Standard- ['Shan5' vaccine gets WHO nod](#)

The Hindu Business Line- [Shantha Biotech's Shan5 vaccine gets WHO approval](#)

Business Today- [Shantha Biotechnics' Shan5 drug gets WHO nod](#)

Publication: The Economic Times

Edition: National

Date: May 6, 2014

Headline: [Sun Pharma denies unit's role in Ranbaxy share run-up before deal](#)

Synopsis: Sun Pharma denied any role by its arm Silver Street Developers LLP in the surge of Ranbaxy share prices in the run-up to \$4 billion merger deal between the two drug majors. "Silver Street Developers LLP had bought the Ranbaxy shares when we had no access to non-public information of Ranbaxy. We hereby confirm that we had not bought any shares in the period from April 1 to April 7," Sun Pharmaceutical Industries said in a statement to stock exchanges.

Similar reports in-

The Financial Express- [Sun Pharma denies insider trading ahead of Ranbaxy deal](#)

The Hindu Business Line- [Sun Pharma denies arm's role in Ranbaxy share price surge](#)

Business Today- [Sun Pharma denies insider trading by arm ahead of Ranbaxy merger deal](#)